Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Peak Asset Management LLC

Peak Asset Management LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 0.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,008 shares of the medical instruments supplier’s stock after selling 5 shares during the period. Becton, Dickinson and makes up about 3.0% of Peak Asset Management LLC’s investment portfolio, making the stock its 8th largest position. Peak Asset Management LLC’s holdings in Becton, Dickinson and were worth $7,889,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Advantus Capital Management Inc raised its stake in Becton, Dickinson and by 0.7% in the first quarter. Advantus Capital Management Inc now owns 21,513 shares of the medical instruments supplier’s stock valued at $3,946,000 after buying an additional 144 shares in the last quarter. Principal Financial Group Inc. raised its stake in Becton, Dickinson and by 1.8% in the first quarter. Principal Financial Group Inc. now owns 318,741 shares of the medical instruments supplier’s stock valued at $58,470,000 after buying an additional 5,514 shares in the last quarter. TLP Group LLC raised its stake in Becton, Dickinson and by 42.0% in the first quarter. TLP Group LLC now owns 1,600 shares of the medical instruments supplier’s stock valued at $294,000 after buying an additional 473 shares in the last quarter. OppenheimerFunds Inc. raised its stake in Becton, Dickinson and by 0.4% in the first quarter. OppenheimerFunds Inc. now owns 8,912 shares of the medical instruments supplier’s stock valued at $1,635,000 after buying an additional 39 shares in the last quarter. Finally, Gofen & Glossberg LLC IL raised its stake in Becton, Dickinson and by 0.3% in the first quarter. Gofen & Glossberg LLC IL now owns 11,980 shares of the medical instruments supplier’s stock valued at $2,198,000 after buying an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 75.71% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) opened at 197.84 on Thursday. The company has a market cap of $42.20 billion, a P/E ratio of 32.86 and a beta of 1.05. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The stock’s 50 day moving average is $198.62 and its 200 day moving average is $187.41.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the business posted $2.35 EPS. The business’s quarterly revenue was down 5.1% on a year-over-year basis. Equities analysts anticipate that Becton, Dickinson and Company will post $9.45 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.48%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

COPYRIGHT VIOLATION WARNING: This piece was first posted by [[site]] and is the sole property of of [[site]]. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at [[permalink]].

Several analysts recently issued reports on BDX shares. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Evercore ISI upgraded shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $186.00 to $200.00 in a research report on Monday, April 24th. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price target for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Royal Bank Of Canada reissued a “hold” rating and issued a $177.00 price objective on shares of Becton, Dickinson and in a research note on Thursday, April 13th. Finally, Bank of America Corporation reissued a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and currently has a consensus rating of “Buy” and an average target price of $194.69.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the completion of the sale, the vice president now directly owns 70,821 shares in the company, valued at approximately $13,171,289.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.